Targovax granted European patent for cancer immunotherapy
October 12, 2020 -- The European Patent Office has granted a patent to clinical stage immuno-oncology firm Targovax for use of its modified adenovirus in combination with checkpoint inhibitors for cancer therapeutics.
AuraVax licenses intranasal vaccine platform
October 12, 2020 -- Vaccine biotechnology firm AuraVax Therapeutics has entered into an exclusive licensing option agreement with the University of Houston for a unique intranasal vaccine technology.
Oncopeptides moves to file for regulatory approvals
October 12, 2020 -- Oncopeptides plans to submit an application for a conditional marketing authorization of melflufen in the European Union, based on the phase II Horizon study in relapsed refractory multiple myeloma.
Glycostem gets orphan drug nod for multiple myeloma cell therapy
October 12, 2020 -- Glycostem Therapeutics has received orphan drug designation by the U.S. Food and Drug Administration for its off-the-shelf natural killer cell product for the treatment of multiple myeloma.
Grifols begins trial for SARS-CoV-2 hyperimmune globulin
October 9, 2020 -- Grifols has started its anti-SARS-CoV-2 hyperimmune globulin clinical trial, named Inpatient Treatment with Anti-Coronavirus Immunoglobulin. The hyperimmune globulin provides a high and consistent concentration of purified neutralizing antibodies that could be used for both prevention and treatment of COVID-19.
Moderna secures $56M for mobile vaccine manufacturing
October 8, 2020 -- Moderna has received $56 million from the Defense Advanced Research Projects Agency to fund manufacturing of nucleic acid vaccines and therapeutics.
Abveris, Immunitas partner on mAbs discovery
October 8, 2020 -- Abveris and Immunitas Therapeutics are partnering on the discovery of monoclonal antibodies (mAbs) to expand Immunitas' therapeutic pipeline.
Lilly to supply COVID-19 therapy to low-income nations
October 8, 2020 -- Eli Lilly and the Bill & Melinda Gates Foundation have launched an initiative to supply low- and middle-income countries with COVID-19 therapeutic antibody treatment.
J&J to supply EU with 200M COVID-19 vaccine doses
October 8, 2020 -- Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine candidate to European Union (EU) member states following approval from regulators.
NCI launches SeroNet
October 8, 2020 -- The U.S. National Cancer Institute (NCI) launched its Serological Sciences Network for COVID-19 (SeroNet) on October 8.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter